PTC Therapeutics to Participate at Upcoming Investor Conferences
Rhea-AI Summary
PTC Therapeutics (NASDAQ: PTCT) said executives will present at three investor conferences in early March 2026: TD Cowen on March 2, Leerink on March 10, and Barclays on March 11.
All presentations will be webcast live via the company’s Events and Presentations page and archived for 30 days. Viewers are advised to connect several minutes early.
Positive
- None.
Negative
- None.
TD Cowen 46th Annual Health Care Conference 2026
Monday, March 2 at 9:50 a.m. ET
Leerink 2026 Global Healthcare Conference
Tuesday, March 10 at 4:20 p.m. ET
Barclays Global Healthcare Conference 2026
Wednesday, March 11 at 8 a.m. ET
The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes before the start of the webcast to ensure a timely connection.
ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.
For More Information:
Investors:
Ellen Cavaleri
+1 (615) 618-6228
ecavaleri@ptcbio.com
Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-to-participate-at-upcoming-investor-conferences-302694067.html
SOURCE PTC Therapeutics, Inc.